Treatment Information

Back

Lung Cancer treatment details. Immunotherapy.

Chiba University, Chiba, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:3City/State/Province:Chiba
Treatments:ImmunotherapyHospital:Chiba University
Drugs:Journal:Link
Date:Feb 2009

Description:

Patients: This study involved 17 patients with advanced and recurrent non-small cell lung cancer. There were five women and twelve men, ranging in age from 43 to 73 years.

Treatment: Patients were treated with immunotherapy, where some immune system cells (called peripheral blood mononuclear cells) were collected from their blood and then combined with a mixture designed to “activate” them. Then, the cells are put back into the patients body.

Toxicity: One patient experienced grade 3 deep vein thrombosis. There were six reports of grade 2 toxicities, which included fever, anemia, and bloody sputum.

Results: The median overall survival was 18.6 months.

Correspondence: Dr. Toshinori Nakayama



Back